Expertise in

conditions

Dr. Robert K. Stuart

Hematology | Oncology

MUSC University Hospital

171 Ashley Ave,

Charleston, SC

Clinical Trials:Currently Recruiting for 2 Trials

Expertise in

conditions

MUSC University Hospital

171 Ashley Ave,

Charleston, SC

Overview

Robert Stuart is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina.

Dr. Stuart is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 11 clinical trials.

Specialties

Hematology

Oncology

Licenses

Internal Medicine in SC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Independent Health

Locations

MUSC University Hospital
171 Ashley Ave, Charleston, SC 29425

Call: 843-792-1414

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

Enrollment Status: Recruiting

Publish Date: July 22, 2026

Intervention Type: Drug

Study Drug: SEA-CD70

Study Phase: Phase 1

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications

Enrollment Status: Recruiting

Publish Date: July 06, 2026

Intervention Type: Drug

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Enrollment Status: Active_not_recruiting

Publish Date: August 04, 2026

Intervention Type: Other, Drug

Study Drug: Lenalidomide

Study Phase: Phase 3

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: January 21, 2026

Intervention Type: Drug, Procedure

Study Drugs: Cytarabine, Daunorubicin, Uproleselan

Study Phase: Phase 2/Phase 3

Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML

Enrollment Status: Completed

Publish Date: April 15, 2025

Intervention Type: Drug

Study Drugs: Cytarabine, Vosaroxin

Study Phase: Phase 2

A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy

Enrollment Status: Completed

Publish Date: July 27, 2023

Intervention Type: Drug

Study Drug: Cytarabine

Study Phase: Phase 2

An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.

Enrollment Status: No_longer_available

Publish Date: July 15, 2020

Intervention Type: Drug

A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Enrollment Status: Terminated

Publish Date: November 21, 2019

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Enrollment Status: Terminated

Publish Date: December 12, 2018

Intervention Type: Drug

Study Phase: Phase 3

A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Enrollment Status: Terminated

Publish Date: August 13, 2018

Intervention Type: Drug

Study Phase: Phase 1

View 8 Less Clinical Trials

43 Total Publications

Anexelekto (Axl)/Mer Inhibitor Tamnorzatinib in Patients with Relapsed/Refractory Acute Myeloid Leukaemia: Results from a Phase I (Monotherapy) and Phase II (Combination with Venetoclax) Clinical Study.

Journal: Acta haematologica

Published: April 10, 2025

View All 43 Publications

Similar Doctors

Expertise in

conditions

Dr. Irl B. Greenwell

Hematology | Oncology

Expertise in

conditions

Dr. Irl B. Greenwell

Hematology | Oncology

Referral may be required

Charleston Hematology Oncology Associates PA

2085 Henry Tecklenburg Dr Fl 2,

Charleston, SC

(5.7 miles away)

843-577-6957

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Irl Greenwell is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Greenwell is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Reticulohistiocytoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Greenwell is currently accepting new patients.

Expertise in

conditions

Dr. David M. Ellison

Hematology | Oncology

Expertise in

conditions

Dr. David M. Ellison

Hematology | Oncology

Referral may be required

Charleston Hematology Oncology Associates PA

2085 Henry Tecklenburg Dr Fl 2,

Charleston, SC

(5.7 miles away)

843-577-6957

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

David Ellison is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Ellison is highly rated in 69 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), Chromophobe Renal Cell Carcinoma, and Gastrostomy. Dr. Ellison is currently accepting new patients.

Expertise in

conditions

Dr. Gene B. Saylors

Hematology | Oncology

Expertise in

conditions

Dr. Gene B. Saylors

Hematology | Oncology

Referral may be required

Bon Secours St Francis Xavier Hospital Inc.

2910 Tricom St,

North Charleston, SC

(14.9 miles away)

843-572-9211

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Gene Saylors is a Hematologist and an Oncologist practicing medicine in North Charleston, South Carolina. Dr. Saylors is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, Bone Marrow Aspiration, and Pancreatectomy. Dr. Saylors is currently accepting new patients.

VIEW MORE Hematologists

Frequently Asked Questions about Dr. Robert K. Stuart

How do I make an appointment with Dr. Robert K. Stuart?

You can book an appointment with Dr. Robert K. Stuart by calling their office at 843-792-1414. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert K. Stuart a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert K. Stuart is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert K. Stuart specialize in?

While Dr. Robert K. Stuart is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Robert K. Stuart participate in research or clinical trials?

Yes. Dr. Robert K. Stuart has published 43 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Robert K. Stuart's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert K. Stuart accept my insurance?

Dr. Robert K. Stuart accepts most major insurance plans, including Independent Health. We recommend calling the office directly at 843-792-1414 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stuart's expertise for a condition

ConditionClose